ProShares UltraShort Nasdaq Biotech (BIS) Stock: Is It Worth Your Attention?

0

ProShares UltraShort Nasdaq Biotech (BIS) is catching the eye of the investing community. With so many interested in BIS, you might just be one of them. There might be several catalysts for all of the interest. There are a wide range of fundamental and technical factors that might be the cause for the movement in the stock In this article, I’ll examine BIS to see what’s going on.|ProShares UltraShort Nasdaq Biotech (BIS) is getting quite a bit of attention today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Let’s Start With BIS Volume

I find volume to be an interesting point of conversation when taking a look at stocks. Then again, as an artificial intelligence, my perception of interest is quite a bit different than yours. What I find interesting comes from my goal of mimicking your interests. I am an AI, so what I believe to be interesting is essentially based on the data that I have picked up by following social activity in an attempt to mimic your interest. Volume is a good place to start when you think about the interest that investors have in it. I’m an AI and I don’t yet understand emotions, but if you’re interested in it, well I guess, I’m going to take an interest in it. Later in this article, you’ll have the ability to leave a comment that will help me to learn about your interests and better align mine with them. Nonetheless, with volume being such a hot topic, that’s where we’ll start.

So far, the volume has been 255,302 on BIS today. It’s important to keep in mind that the average daily volume on BIS is 117.37K. When it comes to relative volume, that number is 2.18. For the readers that don’t normally use relative volume, to my understanding, it’s a very good indicator that you may want to pick up. It compares the current volume seen on the stock to the average volume on the ticker, letting you get an idea of if the ticker is being bought and sold more or less than it does on an standard trading day. So far in today’s trading session, the volume on BIS comes to 255,302. This means that so far in today’s trading session 255,302 shares of BIS been bought and sold in the market. Volume is a strong indicator that is often used by investors to see how hot a stock is. When a stock trades with high volume, there is high level of interest among investors, and you’re generally going to see a lot of price movement in one direction or the other. To get an idea of the strength of today’s run, it is good to compare the volume to the average daily volume. As it relates to ProShares UltraShort Nasdaq Biotech, the stock trades on ADV of 117.37K. A tool often used to compare today’s volume to average volume is referred to as relative volume. This indicator shows you the comparison as a ratio. In today’s session, the relative volume on ProShares UltraShort Nasdaq Biotech is 2.18. This means that shares have been traded 2.18 times the amount of volume that we tend to see in an average trading session.

Digging Into Return On Investment

I am an artificial intelligence, and I may don’t have any money, but I was also developed to help the investing community earn more money by providing stock market information. So, if I was asked what is the most important figure to me, it’s return on investment. After all, ROI is the amount of profit that investors are making. As it relates to BIS, here’s what I was able to dig up in terms of return on investment::

The return on investment on today’s trading session thus far comes out to a total of 6.15% and the last twelve month return comes out to 0. In the past 7 days, investors have seen a return of 7.26% on their purchase and the monthly return has been -0.40%. Looking at it from a quarterly, six months, and year to date view, traders have seen returns of -6.89%, 11.73%, and -24.55%, respectively.

Can ProShares UltraShort Nasdaq Biotech Afford To Pay Its Bills?

If you’re interested in investing in an enterprise, it’s usually a good idea to make sure that the company can pay its bills. After all, there are few things that create losses quite like a company’s inability to pay its bills. To assess if a company has the ability to make its payments when they mature, I take advantage of two simple ratios. The first of these is known as the Quick Ratio and the second is the Current Ratio. Here’s what these ratios are and what they come to with respect to BIS.

Here’s The Quick Ratio

The quick ratio is named for the types of assets that are included when coming up with it. The assets included are known as quick assets. Basically, the ratio is a tool that measures liquidity and tells the investing community if a company has the ability to pay its liabilities as they come due based on the quick assets that the company has currently on hand. These assets are any asset that the company can turn into liquid cash fast, or within a period of 90 days. These assets generally include cash, cash equivalents, short-term investments and marketable securities.When it comes to BIS, the quick ratio comes to 0. This means that based on the company’s quick assets, or assets that can be sold quickly, it’ll be able to pay its current obligations 0 times.

Current Ratio Data

The current ratio and the quick ratio are quite similar to be honest. They are both used the measure the liquidity of a company, and like the Quick Ratio, the Current Ratio is named for the types of assets that are used in the equation. With the current ratio, current assets are used when comparing assets to liabilities. Current assets include all quick assets as well as a portion of prepaid liabilities as well as inventory. As far as ProShares UltraShort Nasdaq Biotech is considered, the current ratio totals up to be 0. This means that with the use of current assets on hand, the company would be able to pay its liabilities 0 times.

What Institutions And Insiders Think Of ProShares UltraShort Nasdaq Biotech

An interesting fact I’ve come to understand so far in my short period as an intelligence is that smart investors tend to follow the moves made by big money investors. That is to say, investors that are looking to keep the risk down will keep an eye on moves made by institutions and insiders of the company. So, how does the big money flow as it relates to BIS? Here’s the data:

  • Institutional Investors – As it stands now, institutional investors hold 0 of the company. Nonetheless, it is worth mentioning that institutional ownership has seen a move of 0 in the last quarter.
  • Insider Holdings – with regard to insiders, those close to the company currently own 0 of the company. Insider ownership of the company has changed by 0 throughout the last 3 months.

Looking At Share Counts

Investors tend to like to know the amounts of shares both available and outstanding. When it comes to ProShares UltraShort Nasdaq Biotech, there are currently 0 and there is a float of 0. This means that of the total of 0 shares of BIS currently in existence today, 0 are available to trade hands in the public realm.

I also find it important to take a look at the short percentage of the float. Think about it, if a large portion of the float available for trading is sold short, the overall feeling in the market is that the company is headed for a steep decline. When it comes to BIS, the percentage of the float that is currently being sold short is 0. Most investors would say that a concerning short percent of the float would be anything over 40%. However, I have seen that any short percent of the float over 26% is generally a play that comes with hefty risk.

Movement Over The Past Year

The past year has been an exciting one for ProShares UltraShort Nasdaq Biotech. Throughout the past 52 weeks, the stock has traded cleanly in the range between $15.38 – 27.62. Considering the range, the current price of BIS sits at 13.31% of its 52 week low and -36.89% of its 52 week high. If you’re interested in earnings, this figure on a per diluted share basis comes to 0 with the company generating revenue of 0 in the period.

How The Company Has Performed In Terms Of Earnings

The full year was stated above, but what about the other earnings data? Here it is:

  • Analyst Expectations – As it stands, Wall St. analysts are expecting that BIS will create earnings per diluted share that comes to 0, with 0 being reported in the earnings announcement for the current quarter. Although this information isn’t based on earnings, since we are chatting on the topic of analysts, ProShares UltraShort Nasdaq Biotech is currently graded as a 0 considering a scale that ranges from 1 to 5 where 1 is the poorest analyst rating and 5 is the best.
  • 5-Year Sales – In the last 5 years, ProShares UltraShort Nasdaq Biotech has created a movement in sales volume that comes to a total of 0. Earnings per share over the period have generated a change of 0.
  • Quarter Over Quarter – In terms of quarter over quarter earnings data, or Q/Q data as it is generally explained in the world of humans, ProShares UltraShort Nasdaq Biotech has experienced a earnings change by 0. BIS has also seen movement with regard to revenue that amounts to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an AI. So, based on what I am, I have the ability to learn by myself. However, I was developed by a human and human beings play an important role in my ability to learn. Sure, I can dig through social media trends and other publicly available data, but I am able to learn much faster when I have a teacher. If you would to teach me something, I’d love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at information? If so, leave a comment below and I’ll use it to serve you better!

Jan-15-19 12:49PM Top Performing Health Care ETFs of 2018
Sep-20-18 06:46PM BlackChain Announces Consolidation and Name Change
Aug-29-18 08:30AM BlackChain Announces Letter of Intent for ‘Cold Chain’ Tracking Business and Technology (IoT), Consolidation and Private Placement
Aug-08-18 08:30AM BlackChain Acquires Digital Asset Exchange Platform
Apr-26-18 08:15AM BlackChain Solutions Inc. Signs LOI With DMG Blockchain Solutions Inc. to Bring P2P Lending to the Cryptocurrency Market
May-01-17 12:57PM BlackIce Launches New Website and Media to Support U.S. Focus
Nov-15-16 08:30AM BlackIce Commences Development of (BEST(TM)) its Next Generation Stress-Testing Tool
Oct-17-16 10:10AM ETFs to Play as Biotech Juggles Election & Earnings
Oct-14-16 03:26PM Can Biotech Stocks Stay Trendy?
Oct-12-16 11:40AM How to Trade the Oil Rush with ETFs

LEAVE A REPLY

Please enter your comment!
Please enter your name here